Erciyes University Faculty of Medicine, Department of Clinical Microbiology, Kayseri, Turkey.
Erciyes University Faculty of Medicine, Department of Hematology, Kayseri, Turkey.
Turk J Haematol. 2014 Jun;31(2):155-60. doi: 10.4274/tjh.2012.0042. Epub 2014 Jun 10.
We aimed to investigate posttransplant Epstein-Barr virus (EBV) and parvovirus B19 DNA in allogeneic stem cell transplant patients between 2009 and 2010.
Forty-five adult patients in whom allogeneic stem cell transplantation was performed between April 2009 and November 2010 in the Erciyes University Faculty of Medicine, Department of Internal Medicine, Division of Hematology and Oncology, were included in the study. EBV and parvovirus B19 DNA positivity was investigated by using real-time polymerase chain reaction technique in 135 plasma samples obtained after transplantation at between 1 and 6 months. Pretransplant serological markers of EBV and parvovirus B19 were provided from patient files.
In 32 (71.1%) of the patients, EBV antibodies in the pretransplantation period were as follows: anti-EBNA-1 IgG (+), VCA IgM (-), and VCA IgG (+). In 2 patients (4.45%), these antibodies were as follows: anti-EBNA-1 IgG (+), VCA IgM (-), and VCA IgG (-). In 1 patient (2.2%), they were as follows: anti-EBNA-1 IgG (-), VCA IgM (-), and VCA IgG (+). EBV serological markers were negative in 2 (2.2%) out of 45 patients before transplantation. There was low DNA positivity (<600 copies/mL) in 4 patients (8.9%), and VCA IgM was negative and VCA IgG was positive in these same 4 patients. In spite of low viral load, there were no symptoms related to EBV, and posttransplant lymphoproliferative disorder (PTLD) did not occur. While in 44 (99.7%) of 45 patients parvovirus B19 IgM was negative and IgG was positive, parvovirus B19 IgM was positive and IgG was negative in 1 (2.3%) patient. Parvovirus B19 DNA was not identified in any of the samples obtained from these 45 patients.
In this study, EBV and parvovirus B19 DNA were investigated in allogeneic stem cell transplant patients. None of the patients developed PTLD and parvovirus B19 DNA positivity was not detected. However, this issue needs to be further evaluated in prospective, multicenter studies with larger series of patients.
我们旨在研究 2009 年至 2010 年间异基因造血干细胞移植患者移植后 EBV 和微小病毒 B19 DNA 的情况。
在 2009 年 4 月至 2010 年 11 月期间，在埃尔吉耶斯大学医学院内科血液学和肿瘤学系进行了异基因造血干细胞移植的 45 名成年患者纳入本研究。使用实时聚合酶链反应技术在移植后 1 至 6 个月内从 135 份血浆样本中检测 EBV 和微小病毒 B19 DNA 阳性。患者档案中提供了 EBV 和微小病毒 B19 的预移植血清学标志物。
在 32 名（71.1%）患者中，移植前 EBV 抗体如下：抗-EBNA-1 IgG（+）、VCA IgM（-）和 VCA IgG（+）。在 2 名患者（4.45%）中，这些抗体如下：抗-EBNA-1 IgG（+）、VCA IgM（-）和 VCA IgG（-）。在 1 名患者（2.2%）中，这些抗体如下：抗-EBNA-1 IgG（-）、VCA IgM（-）和 VCA IgG（+）。在 45 名患者中，有 2 名（2.2%）患者在移植前 EBV 血清学标志物为阴性。4 名患者（8.9%）存在低水平 DNA 阳性（<600 拷贝/ml），这 4 名患者的 VCA IgM 为阴性，VCA IgG 为阳性。尽管病毒载量较低，但没有与 EBV 相关的症状，也没有发生移植后淋巴组织增生性疾病（PTLD）。在 45 名患者中，有 44 名（99.7%）患者的微小病毒 B19 IgM 为阴性，IgG 为阳性，而 1 名（2.3%）患者的微小病毒 B19 IgM 为阳性，IgG 为阴性。从这 45 名患者的所有样本中均未检测到微小病毒 B19 DNA。
在本研究中，我们对异基因造血干细胞移植患者进行了 EBV 和微小病毒 B19 DNA 的检测。所有患者均未发生 PTLD，也未检测到微小病毒 B19 DNA 阳性。然而，这一问题需要在具有更大患者系列的前瞻性、多中心研究中进一步评估。
